Tag:
Latest Headlines
The U.K.'s cost-effectiveness watchdogs have warmed up to Amgen's bone drug Xgeva. The company sweetened its discount offer, and that persuaded the National Institute for Health and Clinical Excellence to let Xgeva in.
The U.K.'s cost-effectiveness watchdog is having second thoughts about Amgen's new bone drug.
The FDA told Amgen no to an expanded use of its cancer treatment Xgeva, one of the company's most important drugs, saying the company could try again with more data.
The FDA's expert advisors didn't buy Amgen's ( $AMGN ) argument for earlier use of its bone drug Xgeva in prostate cancer patients. The idea: Treat advanced prostate cancer patients with...
The FDA isn't convinced that Amgen ( $AMGN ) needs another bone-metastasis indication for its new drug Xgeva . The drug is already approved to treat skeletal side effects in cancer patients, but Amgen
The FDA isn't convinced that Amgen ( $AMGN ) needs another bone-metastasis indication for its new drug Xgeva . The drug is already approved to treat skeletal side effects in cancer patients, but Amgen
Amgen's ( $AMGN ) anemia drugs faltered again in the fourth quarter with sales declining 15% on Aranesp and 18% on Epogen . New bone drugs Xgeva and Prolia beat analyst estimates for their first full
Amgen's ( $AMGN ) incoming CEO has high hopes for this year. Now COO, Robert Bradway says he's looking for revenue growth in 2012, thanks in part to international expansion. Another driver: Sales of
It's a good news-good news day for Amgen ( $AMGN ). The company's new bone drug is gathering indications--and potential sales--like a snowball rolling downhill. Under the name Prolia, the drug won FDA
Fear not, pharma. There really might be hope ahead. Or such is the feeling among analysts chuffed by the early success of three new drugs. You know the ones: Bristol-Myers Squibb's melanoma drug
Press Releases
- From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients
- Industry insists Australian clinical trials are internationally cost competitive contrary to 2012 report
- Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)
- CardioDx Announces Publication of the IMPACT-CARD Trial Demonstrating Use of Corus® CAD Test Influenced Cardiologists' Clinical Management of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease
- Novation 2013 Diagnostic Imaging Watch Highlights Latest Product and Practice Trends
- More Press Releases
Featured Jobs
-
Sr. Manufacturing Process Lead Job
Celgene Corporation - Basking Ridge NJ US -
Import/Export Specialist Job
Celgene Corporation - Basking Ridge NJ US -
Principal Scientist - Biochemistry
Syros Pharmaceuticals - Watertown Massachusetts -
Quality Control Lead
Infinity Pharmaceuticals - Cambridge MA -
Sr. Manufacturing Process Lead Job
Celgene Corporation - Basking Ridge NJ US
Sponsored Links

